Literature DB >> 2465356

Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor.

K Hashimoto1, T C Wun, J Baird, G S Lazarus, P J Jensen.   

Abstract

To investigate the mechanisms by which cutaneous plasminogen activator (PA) may be regulated, we have tested cultured keratinocytes for the presence of PA inhibitors. Using biosynthetic labeling experiments with 35S-methionine in conjunction with specific antibody precipitation, we have shown that human keratinocytes in culture synthesized and secreted both PA inhibitor 1 and PA inhibitor 2. PA inhibitor 1 was present in conditioned media in the inactive form, but it could be detected with reverse phase autography. PA inhibitor 2 was detected by its ability to form complexes with 125I-uPA. Potential therapeutic relevance for cutaneous PA inhibitor 2 was suggested in skin organ culture experiments which demonstrated that purified PA inhibitor 2 from human placenta was able to prevent the acantholytic changes induced by pemphigus IgG.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465356     DOI: 10.1111/1523-1747.ep12277087

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

1.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

2.  Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.

Authors:  A Oikarinen; M Höyhtyä; M Järvinen
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.

Authors:  J Reinartz; H Näher; H Mai; M D Kramer
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study.

Authors:  H Dobrev; L Popova; D Vlashev
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

5.  Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion.

Authors:  J Varani; B Burmeister; R G Sitrin; S B Shollenberger; D R Inman; S E Fligiel; D F Gibbs; K Johnson
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

Review 6.  A perspective of pemphigus from bedside and laboratory-bench.

Authors:  Yasuo Kitajima; Yumi Aoyama
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

7.  Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.

Authors:  Isabelle Bolon; Hong-Ming Zhou; Yves Charron; Annelise Wohlwend; Jean-Dominique Vassalli
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

8.  A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.

Authors:  H McNeill; P J Jensen
Journal:  Cell Regul       Date:  1990-10

9.  Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients.

Authors:  Joanna Narbutt; Joanna Boncela; Katarzyna Smolarczyk; Cezary Kowalewski; Katarzyna Wozniak; Jolanta Dorota Torzecka; Anna Sysa-Jedrzejowska; Czesław S Cierniewski; Aleksandra Lesiak
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

10.  Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris.

Authors:  P J Koch; M G Mahoney; H Ishikawa; L Pulkkinen; J Uitto; L Shultz; G F Murphy; D Whitaker-Menezes; J R Stanley
Journal:  J Cell Biol       Date:  1997-06-02       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.